Greenland Capital Management LP Trims Stake in Pfizer Inc. (NYSE:PFE)

Greenland Capital Management LP trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 53.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,087 shares of the biopharmaceutical company's stock after selling 14,913 shares during the quarter. Greenland Capital Management LP's holdings in Pfizer were worth $347,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. PSI Advisors LLC boosted its stake in shares of Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after acquiring an additional 385 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its holdings in Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after purchasing an additional 391 shares in the last quarter. D Orazio & Associates Inc. boosted its stake in Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton grew its holdings in Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 400 shares in the last quarter. Finally, Oliver Luxxe Assets LLC raised its position in shares of Pfizer by 2.2% during the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after buying an additional 401 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PFE. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Finally, UBS Group decreased their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and an average target price of $31.07.

Pfizer Trading Up 1.4 %

Shares of Pfizer stock traded up $0.30 during trading on Friday, hitting $21.89. The stock had a trading volume of 55,013,451 shares, compared to its average volume of 40,232,439. The stock has a market cap of $124.14 billion, a PE ratio of 15.52, a PEG ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm's fifty day simple moving average is $25.25 and its 200-day simple moving average is $26.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.